ADI-001 is under clinical development by Adicet Bio and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for B-Cell Non-Hodgkin Lymphoma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ADI-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ADI-001 is under development for the treatment of non-Hodgkin’s lymphomas including follicular lymphoma, mantle-cell lymphoma, marginal zone lymphoma, mediastinal lymphoma, diffuse large b cell lymphoma. The therapeutic candidate comprises of allogenic gamma delta T cells expressing chimeric antigen receptors (CARs) directed to CD20. It acts by targeting cells expressing CD20. It is administered via parenteral route. The therapeutic candidate is being developed based on universal immune cell therapy (uICT) platform technology and T cell receptor-like monoclonal antibodies (TCRLs).
It was under development for the treatment of chronic lymphocytic leukemia (CLL), burkitt lymphoma.
Adicet Bio overview
Adicet Bio, formerly resTORbio, is a biotechnology company. The company is engaged in developing allogeneic gamma delta T cell therapies for addressing the unmet medical need of solid tumors and hematological cancers. Adicet Bio’s pre-clinical pipeline includes ADI-001, a CD20 CAR-T cell therapy candidate for the treatment of non-hodgkin’s lymphoma; and ADI-002, a GPC3-targeting chimeric antigen receptor (CAR) for the treatment of hepatocellular carcinoma. It is also advancing the ADI-00x program for multiple solid tumors. Adicet Bio utilizes its proprietary immune cell platform that engineers gamma delta T cells with CARs and T cell receptors to generate T cell receptor-like monoclonal antibodies (TCRLs) directed to intracellular proteome to kill tumor cells. The company works in collaboration with Regeneron Pharmaceuticals Inc to develop engineered immune-cell therapeutics for cancer. It operates in the US. Adicet Bio is headquartered in Boston, Massachusetts, the US.
For a complete picture of ADI-001’s drug-specific PTSR and LoA scores, buy the report here.